Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Respiratory Generics: Big Potential But A Tough Market To Crack

Executive Summary

With GlaxoSmithKline's blockbuster asthma drug Advair facing patent expiration later this year, generic drug makers like Teva and Sandoz are looking to pounce on the opportunity

You may also be interested in...



Financings Of The Fortnight: In The Aftermath Of Facebook IPO, Kythera Steps Up, TVAX And Cancer Genetics Back Off

Plus news on recent financing activity by TVM Capital, Royalty Pharma, Prosonix and Sangart.

Prosonix Extends Series B Financing, Plans Generic Fluticasone Filing

Prosonix receives an extra $9 million for its Series B round as it changes business strategy from contract research to the development of generic respiratory products, based on a novel particle-engineering technology for inhaled powders.

Managing The World’s First Blockbuster Generic: An Interview With Sandoz’s George

Jeff George, global head of Sandoz, talks about enoxaparin, a commitment to quality manufacturing, and investing in differentiated products.

Related Content

Topics

UsernamePublicRestriction

Register

PS052263

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel